Setting and revising antibacterial susceptibility breakpoints

Clinical Microbiology Reviews

Volumn 20, Issue 3, 2007, Pages 391-408

  Turnidge, John ^a   Paterson, David L ^b,c,d  

^a WOMEN S AND CHILDREN S HOSPITAL   (Australia)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE DERIVATIVE; ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; CEFEPIME; CEFMENOXIME; CEFUROXIME AXETIL; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; DAPTOMYCIN; GARENOXACIN; GATIFLOXACIN; GENTAMICIN; GLYCOPEPTIDE; GREPAFLOXACIN; KETOLIDE; LEVOFLOXACIN; LINCOSAMIDE DERIVATIVE; LINEZOLID; MACROLIDE; OXACILLIN; PENICILLIN DERIVATIVE; POLYMYXIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; STREPTOGRAMIN; TETRACYCLINE DERIVATIVE; TOBRAMYCIN; VANCOMYCIN;

ANALYTIC METHOD; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTEREMIA; BACTERIAL PNEUMONIA; BACTERIAL STRAIN; BACTEROIDES FRAGILIS; COAGULASE NEGATIVE STAPHYLOCOCCUS; COMMUNITY ACQUIRED PNEUMONIA; ENTEROBACTER; GENOTYPE PHENOTYPE CORRELATION; HOSPITAL INFECTION; HUMAN; LOWER RESPIRATORY TRACT INFECTION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; OTITIS MEDIA; PSEUDOMONAS AERUGINOSA; REVIEW; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; WILD TYPE;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; BIOLOGICAL MARKERS; DRUG RESISTANCE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 34547402464     PISSN: 08938512     EISSN: None     Source Type: Journal    
DOI: 10.1128/CMR.00047-06     Document Type: Review

References (143)

1. Ambrose, P. G., and R. Quintiliani. 2000. Limitations of single point pharmacodynamic analysis. Pediatr. Infect. Dis. J. 19:769.
2. Ambrose, P. G., S. M. Bhavnani, C. M. Rubino, A. Louie, T. Gumbo, A. Forrest, and G. Drusano. 2007. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin. Infect. Dis. 44:79-86.
3. Ambrose, P. G., D. M. Grasela, T. H. Grasela, J. Passarell, H. B. Mayer, and P. F. Pierce. 2001. Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections. Antimicrob. Agents Chemother. 45:2793-2797.
4. Ambrose, P. G. 2005. Antimicrobial susceptibility breakpoints: PK-PD and susceptibility breakpoints. Treat. Respir. Med. 4(Suppl. 1):5-11.
5. Ambrose, P. G. 2006. Monte Carlo simulation in the evaluation of susceptibility breakpoints: predicting the future: insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy 26:129-134.
6. Amsterdam, D. 2005. Susceptibility testing of antimicrobials in liquid media, p. 61-143. In V. Lorian (ed.), Antibiotics in laboratory medicine, 5th ed. Lippincott Williams & Wilkins, Philadelphia, PA.
7. Andes, D., and W. A. Craig. 2005. Treatment of infections with ESBL-producing organisms: pharmacokinetic and pharmacodynamic considerations. Clin. Microbiol. Infect. 11(Suppl. 6):10-17.
8. Andes, D., R. Walker, S. Ebert, and W. Craig. 1994. Increasing protein binding of cefonicid enhances its in vivo activity in an animal model of infection, abstr. A93. Abstr. 34th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
9. Andes, D., M. L. van Ogtrop, J. Peng, and W. A. Craig. 2002. In vivo pharmacodynamics of a new oxazolidinone (linezolid). Antimicrob. Agents Chemother. 46:3484-3489.
10. Andrews, J. 2001. Determination of minimum inhibitory concentrations. J. Antimicrob. Chemother. 48(Suppl. S1):5-16.
11. Andrews, J. January 2005, posting date. BSAC disc diffusion method for antimicrobial susceptibility testing, version 4, January 2005. British Society for Antimicrobial Chemotherapy, Birmingham, United Kingdom. www.bsac.org.uk. Accessed 5 February 2006.
12. Arakawa, S., T. Matsui, S. Kamidono, Y. Kawada, H. Kumon, K. Hirai, T. Hirose, T. Matsumoto, K. Yamaguchi, T. Yoshida, K. Watanabe, K. Ueno, A. Saito, and T. Teranishi. 1998. Derivation of a calculation formula for breakpoints of antimicrobial agents in urinary tract infections J. Infect. Chemother. 4:97-106.
13. Arbeidsgruppen for Antibiotikaspørsmål. 2006. AFAs brytningspunkter for bakteriers antibiotikafølsomhet, versjon 1.9. Arbeidsgruppen for Antibiotikaspørsmål, Tromso, Norway. www.unn.no/category10274. Accessed 1 November 2006.
14. Arbeidsgruppen for Antibiotikaspørsmål. 29 May 2005, posting date. Nødvendig bakgrunnsmateriale og prosedyrer for etablering og justering av mm-brytningssoner. Arbeidsgruppen for Antibiotikaspø rsmål, Tromso, Norway. www.unn.no/article19775-927.html.
15. Baquero, F., J. Martínez-Beltrán, R. Cánton, and the remaining members of the Mesa Española de Normalización de la Sensibilidad y Resistencia a los Antimicrobianos (MENSURA). 1997. Criterios del grupo MENSURA para la definiciónde los puntos críticos de sensibilidad a los antibióticos. Rev. Esp. Quimioter. 10:103-313.
16. Bell, S. M. 1975. The CDS disc method of antibiotic sensitivity testing (calibrated dichotomous sensitivity test). Pathology 7(Suppl.):1-48.
17. Bell, S. M., B. J. Gatus, J. N. Pham, and D. L. Rafferty. Accessed 1 November 2006. Antibiotic susceptibility testing by the CDS method. The CDS Users Group, Randwick, Australia. www.med.unsw.edu.au/pathology-cds. 2004.
18. Bergan, T., J. N. Bruun, A. Digranes, E. Lingaas, K. K. Melby, and J. Sander. 1997. Susceptibility testing of bacteria and fungi. Scand. J. Infect. Dis. 103(Suppl.):1-36.
19. Blaser, J., B. B. Stone, M. C. Groner, and S. H. Zinner. 1985. Impact of netilmicin regimens on the activities of ceftazidime-netilmicin combinations against Pseudomonas aeruginosa in an in vitro pharmacokinetic model. Antimicrob. Agents Chemother. 28:64-68.
20. Brown, P. D., A. Freeman, and B. Foxman. 2002. Prevalence and predictors of trimethoprim-sulfamethoxazole resistance among uropathogenic Escherichia coli isolates in Michigan. Clin. Infect. Dis. 34:1061-1066.
21. Brunden, M. N., G. E. Zurenko, and B. Kapik. 1992. Modification of the error-rate bounded classification scheme for use with two MIC break points. Diagn. Microbiol. Infect. Dis. 15:135-140.
22. Chien, S.-C., M. C. Rogge, L. G. Gibson, C. Curtin, F. Wong, J. Natarajan, R. R. Williams, C. L. Fowler, W. K. Cheung, and A. Chow. 1997. Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral and intravenous doses. Antimicrob. Agents Chemother. 41:2256-2260.
23. Chitwood, L. A. 1969. Tube dilution antimicrobial susceptibility testing: efficacy of a microtechnique applicable to diagnostic laboratories. Appl. Microbiol. 17:707-709.
24. Clinical and Laboratory Standards Institute. 2001. Development of in vitro susceptibility testing criteria and quality control parameters; approved guideline - 2nd ed. CLSI document M23-A2. CLSI, Wayne, PA.
25. Clinical and Laboratory Standards Institute. 2004. Methods for antimicrobial susceptibility testing of anaerobic bacteria; approved standard - 6th ed. CLSI document M11-A6. CLSI, Wayne, PA.
26. Clinical and Laboratory Standards Institute. 2006. Performance standards for antimicrobial disk susceptibility tests; approved standard - 9th ed. CLSI document M2-A9. CLSI, Wayne, PA.
27. Clinical and Laboratory Standards Institute. 2006. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard - 7th ed. CLSI document M7-A7. CLSI, Wayne, PA.
28. Clinical and Laboratory Standards Institute. 2007. Performance standards for antimicrobial susceptibility testing; 16th informational supplement. CLSI document M100-S17. CLSI, Wayne, PA.
29. Comité de l'Antibiogramme de la Société Française de Microbiologie. February 2006, accession date.Communiqué 005. Société Française de Microbiologie, Paris, France. www.sfm.asso.fr.
30. Commissie Richtlijnen Gevoelighheidsbepalingen. 1996. Standaadisatie van gevoelighheidsbepalingen. Ned. Tijschr. Med. Microbiol. 4:104-106.
31. Commissie Richtlijnen Gevoelighheidsbepalingen. 2000. Interpretie van gevoelighheidsonderzoek en gevoelighheidscriteria voor antibacteriële middelen in Nederland. Ned. Tijdschr. Med. Microbiol. 8:79-81.
32. Craig, B. A. 2000. Modeling approach to diameter breakpoint determination. Diagn. Microbiol. Infect. Dis. 36:193-202.
33. Craig, W. A., and S. C. Ebert. 1991. Killing and regrowth of bacteria in vitro: a review. Scand. J. Infect. Dis. 74(Suppl.):63-70.
34. Craig, W. A., Y. Watanabe, and S. Ebert. 1992. AUC/MIC ratio is the unifying parameter for comparison of the in vivo activity among aminoglycosides, abstr. 49. Abstr. 32nd Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
35. Craig, W. A., S. Ebert, and Y. Watanabe. 1993. Differences in time above MIC required for efficacy of beta-lactams in animal infection models, abstr. 86. Abstr. 33rd Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
36. Craig, W. A. 1993. Qualitative susceptibility tests versus quantitative MIC tests. Diagn. Microbiol. Infect. Dis. 16:231-236.
37. Craig, W. A. 1995. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn. Microbiol. Infect. Dis. 22:89-96.
38. Craig, W. A., and D. Andes. 1996. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. Pediatr. Infect. Dis. J. 15:255-259.
39. Craig, W. A. 1996. Antimicrobial resistance issues of the future. Diagn. Microbiol. Infect. Dis. 25:213-217.
40. Craig. W. A., and S. Gudmundsson. 1996. Postantibiotic effect, p. 296-329. In V. Lorian (ed.), Antibiotics in laboratory medicine, 4th ed. Williams and Wilkins, Baltimore, MD.
41. Craig, W. A. 1998. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26:1-12.
42. Crump, J. A., T. J. Barrett, J. T. Nelson, and F. J. Angulo. 2003. Reevaluating fluoroquinolone breakpoints for Salmonella enterica serotype Typhi and for non-Typhi salmonellae. Clin. Infect. Dis. 37:75-81.
43. Davies, T. A., A. Evangelista, S. Pfleger, K. Bush, D. F. Sahm, and R. Goldschmidt. 2002. Prevalence of single mutations in topoisomerase II genes among levofloxacin-susceptible clinical strains of Streptococcus pneumoniae isolated in the United States in 1992 to 1996 and 1999 to 2000. Antimicrob. Agents Chemother. 46:119-124.
44. Deutches Institut für Normung. 2002. Medical microbiology - susceptibility testing of pathogens to antimicrobial agents. 3. Agar diffusion test. DIN document 58940-. Beuth Verlag GmbH, Berlin, Germany.
45. Deutches Institut für Normung. 2000. Medical microbiology - susceptibility testing of pathogens to antimicrobial agents. 3. Agar diffusion test - data for the interpretation of inhibition zone diameters. DIN document 58940-supplement 1. Beuth Verlag GmbH, Berlin, Germany.
46. Deutches Institut für Normung. 1989. Medical microbiology - susceptibility testing of pathogens to antimicrobial agents. 3. Agar diffusion test - zone diameters with control strains. DIN document 58940-supplement 2. Beuth Verlag GmbH, Berlin, Germany.
47. Deutches Institut für Normung. 2002. Medical microbiology - susceptibility testing of pathogens to antimicrobial agents. 4. Evaluation classes of the minimum inhibitory concentration. DIN document 58940-. Beuth Verlag GmbH, Berlin, Germany.
48. Deutches Institut für Normung. 2004. Medical microbiology - susceptibility testing of pathogens to antimicrobial agents. 4. Evaluation classes of the minimum inhibitory concentration - MIC breakpoints of antibacterial agents. DIN document 58940-supplement 1. Beuth Verlag GmbH, Berlin, Germany.
49. Deutches Institut für Normung. 2003. Medical microbiology - susceptibility testing of pathogens to antimicrobial agents. 6. Determination of the minimum inhibitory concentration (MIC) with the agar dilution method. DIN document 58940-. Beuth Verlag GmbH, Berlin, Germany.
50. Deutches Institut für Normung. 1989. Medical microbiology - susceptibility testing of pathogens to antimicrobial agents. 6. Determination of the minimum inhibitory concentration (MIC) with the agar dilution method - MICs of agents with control strains for the agar dilution method. DIN document 58940-supplement 1. Beuth Verlag GmbH, Berlin, Germany.
51. Deutches Institut für Normung. 2002. Medical microbiology - susceptibility testing of pathogens to antimicrobial agents. 81. Microdilution - special requirements for testing non-fastidious bacteria. DIN document 58940-1 1. Beuth Verlag GmbH, Berlin, Germany.
52. Deutches Institut für Normung. 2002. Medical microbiology - susceptibility testing of pathogens to antimicrobial agents. 82. Microdilution - special requirements for testing fastidious bacteria. DIN document 58940-1. Beuth Verlag GmbH, Berlin, Germany.
53. Deutches Institut für Normung. 2002. Medical microbiology - susceptibility testing of pathogens to antimicrobial agents. 83. Microdilution - special requirements for testing strictly anaerobic bacteria. DIN document 58940-3. Beuth Verlag GmbH, Berlin, Germany.
54. Deutches Institut für Normung. 2002. Medical microbiology - susceptibility testing of pathogens to antimicrobial agents. 10. Criteria for the evaluation of the in vitro efficacy and the admission of new antimicrobial agents. DIN document 58940-10. Beuth Verlag GmbH, Berlin, Germany.
55. Doern, G. V. 1995. The in vitro activity of cefotaxime versus bacteria involved in selected infections of hospitalized patients outside the intensive care unit. Diagn. Microbiol. Infect. Dis. 22:13-17.
56. Drusano, G. L. 1988. Role of pharmacokinetics in the outcome of infections. Antimicrob. Agents Chemother. 32:289-297.
57. Drusano, G. L., S. L. Preston, C. Hardalo, R. Hare, C. Banfield, D. Andes, O. Vesga, and W. A. Craig. 2001. Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint. Antimicrob. Agents Chemother. 45:13-22.
58. Drusano, G. L. 2004. Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'. Nat. Rev. Microbiol. 2:289-300.
59. Drusano, G. L., S. L. Preston, C. Fowler, M. Corrado, B. Weisenger, and J. Kahn. 2004. Relationship between fluoroquinolone area under the curve: minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in eradication of the infecting pathogen, in patients with nosocomial pneumonia. J. Infect. Dis. 189:1590-1597.
60. Dudley, M. N., and P. G. Ambrose. 2000. Pharmacodynamics in the study of drug resistance and establishing in vitro susceptibility breakpoints: ready for prime time. Curr. Opin. Microbiol. 3:515-521.
61. Eagle, H., R. Fleischman, and M. Levy. 1953. Continuous versus discontinuous therapy with penicillin: the effect of interval between injections on therapeutic efficacy. N. Engl. J. Med. 248:481-488.
62. Ellner, P. D., and H. C. Neu. 1981. The inhibitory quotient. A method for interpreting minimum inhibitory concentration data. JAMA 246:1575-1578.
63. Ericsson, H., and J. C. Sherris. 1971. Antibiotic sensitivity testing. Report of an international collaborative study. Acta Pathol. Microbiol. Scand. 217(Suppl. B):1-90.
64. European Committee for Antimicrobial Susceptibility Testing (EUCAST) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID). 2000. Determination of antimicrobial susceptibility test breakpoints. Clin. Microbiol. Infect. 6:570-572.
65. European Committee for Antimicrobial Susceptibility Testing (EUCAST) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID). 2000. Determination of minimum inhibitory concentrations (MICs) of antibacterial agents by agar dilution. Clin. Microbiol. Infect. 6:509-515.
66. European Committee for Antimicrobial Susceptibility Testing (EUCAST) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID). 2000. Terminology relating to methods for the determination of susceptibility of bacteria to antimicrobial agents. Clin. Microbiol. Infect. 6:503-508.
67. European Committee for Antimicrobial Susceptibility Testing (EUCAST) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID). 2000. Determination of minimum inhibitory concentrations (MICs) of antibacterial agents by broth dilution. Clin. Microbiol. Infect. 9:1-7.
68. Falcó, V., B. Almirante, Q. Jordano, L. Calonge, O. del Valle, C. Pigrau, A. M. Planes, J. Gavaldà, and A. Pahissa. 2004. Influence of penicillin resistance on outcome in adult patients with invasive pneumococcal pneumonia: is penicillin useful against intermediately resistant strains? J. Antimicrob. Chemother. 54:481-488.
69. Firsov, A. A., S. N. Vostrov, I. Y. Lubenko, K. Drlica, Y. A. Portnoy, and S. H. Zinner. 2003. In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. Antimicrob. Agents Chemother. 47:1604-1613.
70. Fleming, A. 1929. On the antibacterial action of cultures of a penicillium, with special reference to their use in the isolation of B. influenzae. Br. J. Exp. Pathol. 10:226-236.
71. Forrest, A., D. E. Nix, C. H. Ballow, T. F. Goss, M. C. Birmingham, and J. J. Schentag. 1993. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob. Agents Chemother. 37:1073-1081.
72. Forrest, A., S. Chodosh, M. A. Amantea, D. A. Collins, and J. J. Schentag. 1997. Pharmacokinetics and pharmacodynamics of oral grepafloxacin in patients with acute bacterial exacerbations of chronic bronchitis. J. Antimicrob. Chemother. 40(Suppl. A):45-57.
73. Franklin, C., L. Liolios, and A. Y. Peleg. 2006. Phenotypic detection of carbapenem-susceptible metallo-β-lactamase-producing gram-negative bacilli in the clinical laboratory. J. Clin. Microbiol. 44:3139-3144.
74. Frimodt-Møller, N. 2002. Correlation between pharmacokinetic/pharmacodynamic parameters and efficacy for antibiotics in the treatment of urinary tract infection. Int. J. Antimicrob. Agents 19:546-553.
75. Gehanno, P., G. Lenoir, and P. Berche. 1995. In vivo correlates for Streptococcus pneumoniae penicillin resistance in acute otitis media. Antimicrob. Agents Chemother. 39:271-272.
76. Gerber, A. U., A. P. Vastola, J. Brandel, and W. A. Craig. 1982. Selection of aminoglycoside-resistant variants of Pseudomonas aeruginosa in an in vivo model. J. Infect. Dis. 146:691-697.
77. Gupta, K., T. M. Hooton, and W. E. Stamm. 2001. Increasing antimicrobial resistance and the management of uncomplicated community-acquired urinary tract infections. Ann. Int. Med. 135:41-50.
78. International Organization for Standards. 15 November 2006, posting date. Susceptibility testing of infectious agents and evaluation of performance of antimicrobial susceptibility testing devices. 1. Reference method for testing the in vitro activity of antimicrobial agents against rapidly growing anaerobic bacteria involved in infectious diseases. ISO 20776-1. International Organization for Standards, Geneva, Switzerland. http://www.iso.org/iso/en/CatalogueDetailPage.CatalogueDetail?CSNUMBER=41630.
79. Japanese Society for Chemotherapy. 1990. Method for the determination of minimum inhibitory concentration (MIC) of aerobic bacteria by microdilution method. Chemotherapy (Tokyo) 38:102-105.
80. Japanese Society for Chemotherapy. 1993. Method for the determination of minimum inhibitory concentration (MIC) of fastidious bacteria and anaerobic bacteria by microdilution method. Chemotherapy (Tokyo) 41:183-189.
81. Kahlmeter, G. 16 October 2006, accession date. EUCAST procedure for harmonising and defining breakpoints. EUCAST, Basel, Switzerland. http://www.srga.org/EUCAST/bpsetting.htm.
82. Kahlmeter, G., D. F. J. Brown, F. W. Goldstein, A. P. MacGowan, J. W. Mouton, A. Österland, A. Rodloff, M. Steinbakk, P. Urbaskova, and A. Vatopoulos. 2003. European harmonisation of MIC breakpoints for antimicrobial susceptibility testing of bacteria. J. Antimicrob. Chemother. 52:145-148.
83. Kang, C.-I., S.-H. Kim, W. B. Park, K.-D. Lee, H.-B. Kim, E.-C. Kim, M.-Y.Oh, and K.-W. Choe. 2004. Bloodstream infections due to extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy. Antimicrob. Agents Chemother. 48:4574-4581.
84. Kaplan, S. L. 2002. Management of pneumococcal meningitis. Pediatr. Infect. Dis. J. 21:589-592.
85. Kashuba, A. D. M., A. N. Nafziger, G. L. Drusano, and J. S. Bertino. 1999. Optimizing aminoglycoside therapy for nosocomial pneumonia. Antimicrob. Agents Chemother. 43:623-629.
86. Kellner, J. D., D. W. Scheifele, S. A. Halperin, M. C. Lebel, D. Moore, N. Le Saux, E. L. Ford-Jones, B. Law, W. Vaudry, and Other Members of the Canadian Paediatric Society/Centre for Infectious Disease Prevention and Control, Immunization Monitoring Program. 2002. Outcome of penicillin-nonsusceptible Streptococcus pneumoniae meningitis: a nested case-control study. Pediatr. Infect. Dis. J. 21:903-909.
87. Kerrn, M. B., N. Frimodt-Møller, and F. Espersen. 2003. Effects of sulfamethizole and amdinocillin against Escherichia coli strains (with various susceptibilities) in an ascending urinary tract infection mouse model. Antimicrob. Agents Chemother. 47:1002-1009.
88. Knudsen, J. D., K. Fuursted, F. Espersen, and N. Frimodt- Møller. 1997. Activities of vancomycin and teicoplanin against penicillin-resistant pneumococci in vitro and in vivo and correlation to pharmacokinetics parameters in the mouse peritonitis model. Antimicrob. Agents Chemother. 41:1910-1915.
89. Knudsen, J. D., K. Fuursted, S. Raber, F. Espersen, and N. Frimodt-Møller. 2000. Pharmacodynamics of glycopeptides in the mouse peritonitis model of Streptococcus pneumoniae or Staphylococcus aureus infection. Antimicrob. Agents Chemother. 44:1247-1254.
90. Koeth, L. M., A. King, H. Knight, J. May, L. A. Miller, I. Phillips, and J. A. Poupard. 2000. Comparison of cation-adjusted Mueller-Hinton broth with Iso-Sensitest broth for the NCCLS broth microdilution method. J. Antimicrob. Chemother. 46:369-376.
91. Kronvall, G., G. Kahlmeter, E. Myrne, and M. F. Galas. 2003. A new method for normalized interpretation of antimicrobial resistance from disk test results for comparative purposes. Clin. Microbiol.Infect.9:120-132.
92. Kronvall, G. 2003. Determination of the real standard distribution of susceptible strains in zone histograms. Int. J. Antimicrob. Agents 22:7-13.
93. Kronvall, G., I. Karlsson, M. Walder, M. Sörberg, and L. E. Nisson. 2006. Epidemiological MIC cut-off values for tigecycline calculated from Etest values using normalized resistance interpretation. J. Antimicrob. Chemother. 57:498-505.
94. Leggett, J. E., B. Fantin, S. Ebert, K. Totsuka, B. Vogelman, W. Calame, H. Mattie, and W. A. Craig. 1989. Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models. J. Infect. Dis. 159:281-282.
95. MacGowan, A., and R. Wise. 2001. Establishing MIC breakpoints and the interpretation of in vitro susceptibility tests. J. Antimicrob. Chemother. 48(Suppl. S1):17-28.
96. MacGowan, A., C. Rogers, and K. Bowker. 2003. In vitro models, in vivo models, and pharmacokinetics: what can we learn from in vitro models? Clin. Infect. Dis. 33(Suppl. 3):S214-S220.
97. McDonald, P. J., B. H. Wetherall, and H. Pruul. 1981. Postantibiotic leukocyte enhancement: increased susceptibility of bacteria pretreated with antibiotics to activity of leukocytes. Rev. Infect. Dis. 3:38-44.
98. Mesa Española de Normalización de la Sensibilidad y Resistencia a los Antimicrobianos (MENSURA). 2000. Recommedaciones del grupo MENSURA para la selecciónde antimicrobianos en el studio de la sensibilidad y criterios para la interpretaciondel antibiograma. Rev. Esp. Quimioter. 13:73-86.
99. Metzler, C. M., and R. M. DeHaan. 1974. Susceptibility tests of anaerobic bacteria: statistical and clinical considerations. J. Infect. Dis. 30:88-594.
100. Miller, L. G., and A. W. Tang. 2004. Treatment of uncomplicated urinary tract infections in an era of increasing antimicrobial resistance. Mayo Clin. Proc. 79:1048-1054.
101. Moise, P. A., A. Forrest, S. M. Bhavnani, M. C. Birmingham, and J. J. Schentag. 2000. Area under the inhibitory curve and a pneumonia scoring system for predicting outcomes of vancomycin therapy for respiratory infections by Staphylococcus aureus. Am. J. Hosp. Pharm. 57(Suppl. 2):S4-S9.
102. Moise-Broder, P. A., A. Forrest, M. C. Birmingham, and J. J. Schentag. 2004. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin. Pharmacokinet. 43:925-942.
103. Moore, R. D., P. S. Lietman, and C. R. Smith. 1987. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimum inhibitory concentration. J. Infect. Dis. 155:93-99.
104. Mouton, J. W., J. E. Degener, B. van Klingeren, A. J. de Neeling, and Commissie Richtlijnen Gevoelighheidsbepalingen. 2000. Het vastellen van gevoelighehidscriteria voor antibcateriele middelen in Nederland: verleden, heden en toekomst. Ned. Tijdschr. Med. Microbiol.8:73-78.
105. Mouton, J. W. 2003. Impact of pharmacodynamics on breakpoint selection for susceptibility testing. Infect. Dis. Clin. N. Am. 17:579-598.
106. Odenholt Tornqvist, I., S. E. Holm, and O. Cars. 1991. Pharmacodynamic effects of subinhibitory antibiotic concentrations. Scand. J. Infect. Dis. 74(Suppl.):94-101.
107. Olivier, C., R. Cohen, P. Begué, and D. Floret. 2000. Bacteriologic outcome of children with cefotaxime- or ceftriaxone-susceptible and -nonsusceptible Streptococcus pneumoniae meningitis. Pediatr. Infect. Dis. J. 19:1015-1017.
108. Pallares, R., J. Linares, M. Vadillo, C. Cabellos, F. Manresa, P. F. Viladrich, R. Martin, and F. Gudiol. 1995. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N. Engl. J. Med. 333:474-480.
109. Paterson, D. L., and R. A. Bonomo. 2005. Extended-spectrum beta-lactamases: a clinical update. Clin. Microbiol. Rev. 18:657-686.
110. Paterson, D. L., W.-C. Ko, A. Von Gottberg, J. M. Casellas, L. Mulazimoglu, K. P. Klugman, R. A. Bonomo, L. B. Rice, J. G. McCormack, and V. L. Yu. 2001. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical laboratory. J. Clin. Microbiol. 39:2206-2212.
111. Preston, S. L., G. L. Drusano, A. L. Herman. C. L. Fowler, A. T. Chow, B. Dornseif, V. Reichl, J. Natarajan, and M. Corrado. 1998. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA 279:125-129.
112. Rasheed, J. K., and F. C. Tenover. 2003. Detection and characterization of antimicrobial resistance genes in bacteria, p. 1196-1212. In P. R. Murray, E. J. Baron, J. H. Jorgensen, M. A. Pfaller, and R. H. Yolken (ed.), Manual of clinical microbiology, 8th ed., vol. 1. ASM Press, Washington, DC.
113. Raz, R., B. Chazan, Y. Kennes, R. Colodner, E. Rottensterrich, M. Dan, W. Stamm, and the Israeli Urinary Tract Infection Group. 2002. Empiric use of trimethoprim-sulfamethoxazole (TMP-SMX) in the treatment of women with uncomplicated urinary tract infections, in a geographical area with a high prevalence of TMP-SMX-resistant uropathogens. Clin. Infect. Dis. 24:1165-1169.
114. Rosco Diagnostica. 2005-2006. User's guide. Neo-Sensitabs susceptibility testing, 17th ed. Rosco Diagnostica A/C, Taastrup, Denmark.
115. Saito, A. 1995. Clinical breakpoints for antimicrobial agents in pulmonary infections and sepsis: report of the Committee for Japanese Standards for Antimicrobial Susceptibility Testing of Bacteria. J. Infect. Chemother. 1:83-88.
116. Saito, A., T. Inamatsu, J. Okada, T. Oguri, H. Kanno, N. Kusano, H. Kumon, K. Yamaguchi, A. Watanabe, and K. Watanabe. 1999. Clinical breakpoints in pulmonary infections and sepsis: new antimicrobial agents and supplemental information for some agents already released. J. Infect. Chemother. 5:223-226.
117. Sakoulas, G., P. A. Moise-Broder, J. Schentag, A. Forrest, R. C. Moellering, Jr., and G. M. Eliopoulos. 2004. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob. Agents Chemother. 42:2398-2402.
118. Schentag, J. J., I. L. Smith, D. J. Swanson, C. DeAngelis, J. E. Fracasso, A. Vari, and J. W. Vance. 1984. Role of dual individualization with cefmenoxime. Am. J. Med. 77:43-50.
119. Sirot, J., P. Courvalin, and C.-J. Soussy. 1996. Definition and determination of in vitro antibiotic susceptibility breakpoints for bacteria. Clin. Microbiol. Infect. 2(Suppl. 1):S5-S10.
120. Snydman, D. R., G. J. Cuchural, L. McDermott, and M. Gill. 1992. Correlation of various in vitro testing methods with clinical outcomes in patients with Bacteroides fragilis group infections treated with cefoxitin: a retrospective study. Antimicrob. Agents Chemother. 36:540-544.
121. Sociedad Españolade Enfermedades Infecciosas y Microbiología Clínica. 2000. Procedimientos en microbiología clínica: métados básicos para el estudio de la sensibilidad a los antimicrobianos. Sociedad Españolade Enfermedades Infecciosas y Microbiología Clínica, Madrid, Spain. http://www.seimc.org/protocolos/microbiologia/.
122. Stamey, T. A., W. R. Fair, M. M. Timothy, M. A. Millar, G. Mihara, and Y. C. Lowery. 1974. Serum versus urinary antimicrobial concentrations in cure of urinary-tract infections. N. Engl. J. Med. 291:1159-1163.
123. Swedish Reference Group on Antibiotics. 11 February 2004, revision date. The principles behind SRGA breakpoints. Swedish Reference Group on Antibiotics, Vaxjo, Sweden. www.srga.org. Accessed 5 February 2006.
124. Swenson, J. M., J. F. Hindler, and J. H. Jorgensen. 2003. Special phenotypic methods for detecting antibacterial resistance, p. 1178-1195. In P. R. Murray, E. J. Baron, J. H. Jorgensen, M. A. Pfaller, and R. H. Yolken (ed.), Manual of clinical microbiology, 8th ed., vol. 1. ASM Press, Washington, DC.
125. Szabó, D., R. A. Bonomo, F. Silveira, A. W. Pasculle, C. Baxter, P. K. Linden, A. M. Hujer, K. M. Hujer, K. Deeley, and D. L. Paterson. 2005. SHV-type extended-spectrum beta-lactamase production is associated with reduced cefepime susceptibility in Enterobacter cloacae. J. Clin. Microbiol. 43:5058-5064.
126. Tam, V. H., P. S. McKinnon, R. L. Akins, M. L. Ryback, and G. L. Drusano. 2002. Pharmacodynamics of cefepime in patients with gram-negative infections. J. Antimicrob. Chemother. 50:425-428.
127. Tam, V. H., P. S. McKinnon, R. L. Akins, G. L. Drusano, and M. L. Ryback. 2003. Pharmacokinetics and pharmacodynamics of cefepime in patients with various degrees of renal function. Antimicrob. Agents Chemother. 47:1853-1861.
128. Turnidge, J. D. 1998. The pharmacodynamics of β-lactams. Clin. Infect. Dis. 27:10-22.
129. Turnidge, J. 1999. Pharmacokinetics and pharmacodynamics of fluoroquinolones. Drugs 58(Suppl. 2):29-36.
130. Turnidge, J. D., and J. M. Bell. 2005. Antimicrobial susceptibility on solid media, p. 8-60. In V. Lorian (ed.), Antibiotics in laboratory medicine, 5th ed. Lippincott Williams & Wilkins, Philadelphia, PA.
131. Turnidge, J., and G. Bordash. 2007. Statistical methods for establishing quality control ranges for antibacterial agents in Clinical and Laboratory Standards Institute susceptibility testing. Antimicrob. Agents Chemother. 51:2483-2488.
132. Turnidge, J., G. Kahlmeter, and G. Kronvall. 2006. Statistical characterisation of bacterial wild-type MIC value distributions and the determination of epidemiological cut-off values. Clin. Microbiol. Infect. 12:418-425.
133. Van Wart, S., L. Phillips, E. A. Ludwig, R. Russo, D. A. Gajjar, A. Bello, P. G. Ambrose, C. Costanzo, T. H. Grasela, R. Echols, and D. M. Grasela. 2004. Population pharmacokinetics of garenoxacin in patients with community-acquired respiratory tract infections. Antimicrob. Agents Chemother. 48:4766-4777.
134. Vogelman, B., S. Gudmundsson, J. Turnidge, J. Leggett, and W. A. Craig. 1988. In vivo postantibiotic effect in a thigh infection in neutropenic mice. J. Infect. Dis. 157:287-298.
135. Vogelman, B., S. Gudmundsson, J. Leggett, J. Turnidge, S. Ebert, and W. A. Craig. 1988. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J. Infect. Dis. 158:831-847.
136. Walsh, T. R., M. A. Toleman, L. Poirel, and P. Nordmann. 2005. Metallo-β-lactamases: the quiet before the storm? Clin. Microbiol. Rev. 18:306-325.
137. Watanabe, Y., S. Ebert, and W. Craig. 1992. AUC/MIC ratio is the unifying parameter for comparison of the in-vivo activity among fluoroquinolones, abstr. 42. Abstr. 32nd Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
138. Werkgroep Richtlijnen Gevoelighheidsbepalingen. 1981. Standaadisatie van gevoelighheidsbepalingen. RIVM, Bilthoven, The Netherlands.
139. Werkgroep Richtlijnen Gevoelighheidsbepalingen. 1990. Standaadisatie van gevoelighheidsbepalingen, supplement e. RIVM, Bilthoven, The Netherlands.
140. Werkgroep Richtlijnen Gevoelighheidsbepalingen. 1991. Standaadisatie van gevoelighheidsbepalingen, supplement e, bijlage. RIVM, Bilthoven, The Netherlands.
141. Wilder, M. A., and P. G. Ambrose. 2005. The breakpoint, p. 1-7. In V. Lorian (ed.), Antibiotics in laboratory medicine, 5th ed. Lippincott Williams & Wilkins, Philadelphia, PA.
142. Yu, V. L., C. C. C. Chiou, C. Feldman, A. Ortqvist, J. Rello, A. J. Morris, L. M. Baddour, C. M. Luna, D. R. Snydman, M. Ip, W. C. Ko, B. F. Chedid, A. Andremont, and K. Klugman. 2003. An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome. Clin. Infect. Dis. 37:320-327.
143. Zelenitsky, S. A., G. K. Harding, S. Sun, K. Ubhi, and R. E. Ariano. 2003. Treatment and outcome of Pseudomonas aeruginosa bacteremia: an antibiotic pharmacodynamic analysis. J. Antimicrob. Chemother. 52:668-674.